Blue Water Acquisition Corp III

Blue Water Acquisition Corp III

BLUW
Blue Water Acquisition Corp IIIUS flagNASDAQ Global Select
10.32
USD
+0.01
- -
333.42MMarket Cap
2024 Y
2025 Y
TTM
Revenue per Share
- -
- -
- -
Basic EPS, GAAP
- -
0.23
0.26
Free Cash Flow per Basic Share
- -
-0.05
-0.04
Dividend per Share
- -
0.01
- -
Book Value per Share
- -
12.17
9.95
Tangible Book Value per Share
- -
12.17
9.95
Basic Weighted Avg Shares
28
21
25
Sales/Revenue/Turnover
- -
- -
- -
Operating Margin (%)
- -
- -
- -
Depreciation Expense
- -
- -
- -
Net Income, GAAP
- -
5
7
Effective Tax Rate (%)
- -
- -
- -
Profit Margin (%)
- -
- -
- -
Working Capital
- -
- -
- -
LT Debt
- -
- -
- -
Total Equity
- -
250
252
Return on Invested Capital (%)
- -
-0.86
-1.05
Return on Capital (%)
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -

Capital Structure

FRC

in mil. unless spec.
Dec'25
Mar'26
ST Debt
- -
- -
LT Borrowings
- -
- -
LT Finance Leases
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
Shares Outstanding
32
32
Market Capitalization
247
260

Working Capital

FRC

in mil. unless spec.
Dec'25
Mar'26
Total Current Assets
- -
- -
Cash, Cash Equivalents & STI
- -
- -
Accounts Receivable, Net
- -
- -
Inventories
- -
- -
Total Current Liabilities
- -
- -
Payables & Accruals
- -
- -
ST Debt
- -
- -
Deferred Revenue
- -
- -

Growth Rates

FRC

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-1,061,506.98%
Free Cash Flow
- -
- -
- -
Net Income, GAAP
- -
- -
-9,716.04%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
0.04
0.07
- -
0.23
2026
0.06
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -

Company Description

APIChatGPT
CEO
Kevin J. McGurn
Full Time Employees
2
Sector
Financial Services
Industry
Shell Companies
Address
15 East Putnam Avenue Mountainside NJ United States of America 06830
IPO Date
Feb 9, 2021
Business
Blue Water Acquisition Corp. III, a blank check company formed for the purpose of effecting a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, or similar business combination with one or more businesses, primarily targets high-potential companies in the biotechnology, healthcare, technology, and artificial intelligence sectors; it offers no current operational products or services beyond its SPAC structure, which provides public market access through de-SPAC transactions for private entities in these industries. Founded in 2024 and headquartered at 15 E. Putnam Avenue, Suite 363, Greenwich, Connecticut, the company operates principally in the United States with a global acquisition mandate. In June 2025, it completed an upsized $253 million initial public offering of 25.3 million units at $10 each on Nasdaq under symbols BLUW and BLUWW, fully exercising the underwriters' over-allotment option; in September 2025, it submitted a $10 billion unsolicited bid for PDV Holding Inc., parent of Citgo Petroleum Corp., including a $3.2 billion settlement for defaulted PDVSA 2020 bondholders, though a U.S. court denied its request to extend the sale hearing and it later suspended participation in the process; most recently, on November 25, 2025, it executed a sponsor change via a Purchase Agreement, transferring control to a new sponsor that acquired Class B shares and private units for $7.2 million, resulting in a complete management and board overhaul.

Company News

APIChatGPT
  • BLUW Stock: 11 Things to Know About Blue Water SPAC Amid Short-Squeeze Rumors

  • A handful of heavily shorted SPACs are being squeezed higher as investors redeem shares ahead of final merger

  • Blue Water Acquisition Corp. Announces Date for Special Meeting of Stockholders to Vote on Transaction With Clarus Therapeutics, Inc.

  • Clarus Therapeutics And HavaH Therapeutics Announce Licensing Agreement For Product To Treat Androgen-Dependent Inflammatory Breast Disease And Certain Forms Of Breast Cancer

  • SHAREHOLDER ALERT: Monteverde & Associates PC Announces an Investigation of Blue Water Acquisition Corp. - BLUW